☆ 4.7 Article

Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study

VACCINES (2023)

Related references

Note: Only part of the references are listed.

Review Hematology

COVID-19 convalescent plasma

Aaron A. R. Tobian et al.

Summary: COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19 that works through the mediation of antibodies and is primarily effective for elderly outpatients in the early stages of the disease. However, it is not effective for hospitalized patients with moderate to severe disease. Collection of CCP should be as close as possible to the time and location of the patient.

BLOOD (2022)

Add to Collection

Article Infectious Diseases

Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study

Zoltan Voko et al.

Summary: This observational study in Hungary estimated the effectiveness of five different vaccines in preventing SARS-CoV-2 infection and COVID-19-related death, and found that these vaccines have high or very high effectiveness in these areas.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Gastroenterology & Hepatology

Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis

Binu V. John et al.

Summary: This study investigated the outcomes of postvaccination COVID-19 in patients with cirrhosis and found that these infections are associated with reduced mortality.

HEPATOLOGY (2022)

Add to Collection

Article Virology

Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases

Athanasios-Dimitrios Bakasis et al.

Summary: The study demonstrates that mRNA-based vaccines against SARS-CoV-2 are safe and effective in patients with liver diseases. However, PWLD receiving immunosuppressive treatment and those of advanced age should be closely monitored after vaccination.

VIRUSES-BASEL (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method

Rolf Teschke et al.

Summary: This systematic review found that drug-induced liver injury (DILI) is common in COVID-19 patients, especially due to the use of antiviral drugs. Most patients have a favorable outcome, but there are also fatal cases.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Pharmacology & Pharmacy

Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19

Suyu Gao et al.

Summary: This study investigated the association between drug treatments and drug-induced liver injury (DILI) in hospitalized patients with COVID-19. The results showed that patients who received antibiotics, antifungal agents, and corticosteroids had a higher risk of DILI. Additionally, parenteral nutrition and enteral nutrition were identified as risk factors for liver injury.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — United States, June 2021–February 2022

Ian D. Plumb et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Immunology

Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of Antibody Titers

Katharina Willuweit et al.

Summary: Patients with liver cirrhosis showed a favorable initial outcome after vaccination with the COVID-19 vaccine, but the antibody response deteriorated rapidly over time, highlighting the importance of early booster immunization for this group of patients.

VACCINES (2022)

Add to Collection

Review Gastroenterology & Hepatology

Covid-19 and alcohol associated liver disease

Sasha Deutsch-Link et al.

Summary: The COVID-19 pandemic has had significant impacts on the health status of individuals with alcohol use disorder and alcohol-associated liver disease, including increased alcohol use, reduced access to treatment, and challenges in managing the downstream effects.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Article Gastroenterology & Hepatology

Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

Thomas Marjot et al.

Summary: The COVID-19 pandemic has posed challenges to the hepatology community, and the European Association for the Study of the Liver has provided a summary of the latest data on the impact of COVID-19 on the liver and issued guidance for patients with chronic liver disease, hepatobiliary cancer, and previous liver transplantation.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Immunology

Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant

Veronika Muller et al.

Summary: This study found that additional booster vaccinations given to elderly individuals infected with the SARS-CoV-2 Delta variant can significantly reduce the risk of infection, hospital admission, and 28-day all-cause mortality.

VACCINES (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022

Anne M. Hause et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Gastroenterology & Hepatology

SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination

Andrew M. Moon et al.

Summary: This study describes cases of SARS-CoV-2 infection among patients with chronic liver disease and liver transplant recipients after receiving at least one dose of COVID-19 vaccine. The results suggest that vaccination against SARS-CoV-2 leads to favorable outcomes, with fully vaccinated patients experiencing no mechanical ventilation, ICU admissions, or deaths when facing COVID-19.

HEPATOLOGY COMMUNICATIONS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort

Jasmohan S. Bajaj et al.

Summary: Patients with cirrhosis and COVID-19 had higher mortality compared with patients with COVID-19 alone, but similar mortality compared with patients with cirrhosis alone. Charlson Comorbidity Index (CCI) was the only independent predictor of mortality in the entire matched cohort.

GUT (2021)

Add to Collection

Article Gastroenterology & Hepatology

Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study

Donghee Kim et al.

Summary: The study identified that alcohol-related liver disease, decompensated cirrhosis, and hepatocellular carcinoma are risk factors predicting higher mortality in patients with chronic liver disease and COVID-19, while Hispanic ethnicity and decompensated cirrhosis are associated with severe COVID-19.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

Thomas Marjot et al.

Summary: This international registry study demonstrates that patients with cirrhosis are at increased risk of death from COVID-19. Mortality from COVID-19 was particularly high among patients with more advanced cirrhosis and those with alcohol-related liver disease.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Letter Gastroenterology & Hepatology

Cirrhosis Is Associated With High Mortality and Readmissions Over 90 Days Regardless of COVID-19: A Multicenter Cohort

Jasmohan S. Bajaj et al.

LIVER TRANSPLANTATION (2021)

Add to Collection

Article Gastroenterology & Hepatology

AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID‐19 Infection in Patients with Liver Disease

Oren K. Fix et al.

HEPATOLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

COVID-19 and liver disease: mechanistic and clinical perspectives

Thomas Marjot et al.

Summary: This article provides insights into the mechanistic and clinical aspects of COVID-19 in the context of liver disease, discussing viral hepatotropism, differential expression of viral receptors on liver cell types, and liver histology features in COVID-19 patients. It also highlights the impact of COVID-19 on patients with pre-existing chronic liver disease and the potential strategies for managing these patients, including vaccination.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Review Multidisciplinary Sciences

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Victoria Rotshild et al.

Summary: New COVID-19 vaccines from Pfizer and Moderna showed the highest efficacy in preventing symptomatic COVID-19 in adults. There was no significant difference in the prevention of symptomatic disease among the elderly population. mRNA-1273 and Gam-COVID-Vac vaccines were associated with a higher probability of protection against severe COVID-19 compared to other vaccines.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study

Jin Ge et al.

Summary: The study used an electronic health record database to describe outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis, finding that patients with cirrhosis infected with SARS-CoV-2 had an increased risk of mortality.

GASTROENTEROLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Effect of COVID-19 on Pre-existing Liver disease: What Hepatologist Should Know?

Praveen Sharma et al.

Summary: COVID-19 patients may exhibit liver enzyme derangement in 15-55% of cases, with factors like advanced age, hypertension, diabetes, obesity, malignancy, and cardiovascular disease predisposing them to severe disease and hospitalization. Pre-existing liver diseases, particularly cirrhosis, can increase the severity and mortality of COVID-19. Immunosuppression should be reduced in patients with autoimmune liver disease, and certain medications like hydroxychloroquine and remdesivir have been found to be safe for patients with cirrhosis and COVID-19.

JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study

Shailendra Singh et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

Shiv Kumar Sarin et al.

HEPATOLOGY INTERNATIONAL (2020)

Add to Collection

Letter Gastroenterology & Hepatology

Liver injury in remdesivir-treated COVID-19 patients

Rosa Zampino et al.

HEPATOLOGY INTERNATIONAL (2020)

Add to Collection

Article Gastroenterology & Hepatology

High rates of 30-day mortality in patients with cirrhosis and COVID-19

Massimo Iavarone et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment

Lorinc Polivka et al.

JOURNAL OF GLOBAL HEALTH (2020)

Add to Collection

Review Pharmacology & Pharmacy

Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles

Karin Weissenborn

DRUGS (2019)

Add to Collection

Letter Gastroenterology & Hepatology

Influenza virus infection as precipitating event of acute-on-chronic liver failure

Andreas Schuette et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure

Tianzhou Wu et al.

GUT (2018)

Add to Collection

Article Gastroenterology & Hepatology

NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis

Jacqueline G. O'Leary et al.

HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure

Rajiv Jalan et al.

JOURNAL OF HEPATOLOGY (2015)

Add to Collection

Article Gastroenterology & Hepatology

Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis

Richard Moreau et al.

GASTROENTEROLOGY (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.